What is DSIP?
DSIP stands for delta sleep-inducing peptide, a nine-amino-acid neuropeptide named from older sleep-physiology observations.[1][2][3]
The name is stronger than the practical evidence. DSIP is discussed for sleep, stress, pain, and withdrawal contexts, but the literature is older, mixed, and not a modern approved insomnia-drug program.[1][2][3]
DSIP is not a guaranteed sleep switch. It is better framed as a neuropeptide with sleep-related history and limited current clinical confidence.[1][2][3] For more context, read the DSIP side-effect evidence discussion.
What DSIP is investigated for
DSIP evidence is grouped by practical use case and injectable and transdermal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Sleep quality and sleep architecture
Injectable
Sleep quality and sleep architecture
Injectable
Pain modulation
Injectable
Pain modulation
Injectable
Stress response modulation
Injectable
Stress response modulation
Injectable
Stroke neurorecovery
Injectable
Stroke neurorecovery
Injectable
Evidence snapshot
Overall confidence
DSIP has older sleep-focused human literature plus mechanistic interest, but practical usefulness remains uncertain. Modern insomnia-level evidence is weak.[1][2][3][4]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
Older human sleep literature exists but does not establish a modern insomnia treatment.[1][2][3][4]
Animal / preclinical
Mechanistic and early clinical observations support sleep-related interest, with weaker support for stress and pain outcomes.[1][2][3][4]
Mechanism support
DSIP has been studied around sleep architecture, stress-axis modulation, pain, and neuroendocrine signaling. The proposed effect is state modulation rather than a sedative-hypnotic drug profile.[1][2][3][4]
Forms & administration
DSIP has injectable research presentations and experimental transdermal preparations. Assisted skin delivery remains laboratory research, without an established human product or schedule. Preparation and delivered amount depend on the formulation.[13][1][2][16]
Dosing & protocols
These ranges are general reference points, not personal dosing instructions.
Typical Range
Injectable protocols use 100-300 mcg per dose. Intranasal protocols use 300 mcg per dose.[13][1][2][17]
Frequency
Injectable and intranasal protocols are usually taken once nightly.[13][1][2][17]
Timing Considerations
Cycle Length
Injectable cycles run 2-6 weeks. Intranasal courses run 5-10 days.[13][1][2][17]
What to expect
First few nights
Injectable DSIP sleep-oriented use may change sleep onset, nighttime awakenings, dream intensity, or morning restfulness.[1][2][3][4][13]
Weeks 2-4
Injectable sleep blocks may show as steadier sleep continuity, recovery feel, and next-day alertness.[1][2][3][4][13]
After stopping
Sleep patterns may drift back toward baseline after injectable DSIP exposure ends if the benefit depends on continued use.[1][2][3][4][13]
Safety profile
DSIP safety is a sleep-neuropeptide question: next-day sedation, dream changes, headache, sedative combinations, and limited modern human data are the main issues.[1][2][3][4]
Who DSIP is not for
Route-specific avoid and medical-review notes:
Drug & supplement interactions
Documented interactions are separated from theoretical or route-specific cautions.
Theoretical interactions
- Sleep meds / sedatives / alcohol
Benzodiazepines, Z-drugs, antihistamine sleep aids, alcohol, or sedating supplements can compound next-day impairment; this is a theoretical neuroactive caution.[1][2][3][4]
- Opioids / gabapentinoids
Opioids, gabapentin, or pregabalin can raise the consequence of added sleepiness or poor coordination; this is a theoretical neuroactive caution.[1][2][3][4]
- Stimulants / caffeine
Stimulants or high caffeine can counter sleep effects and make sleep-response tracking unreliable; this is a theoretical neuroactive caution.[1][2][3][4]
Regulatory status
United States
In the U.S. as of 2026-06-21, DSIP is not FDA-approved for the reviewed injectable route. FDA compounding safety-risk materials flag this substance or close naming variant, so the 503A row should be read as a safety-risk bucket, not approval.[21][13][14][19][20]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Injectable | Not Approved DSIP is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[13][14][19][20] | Flagged FDA safety-risk materials flag emideltide/DSIP for immunogenicity, peptide impurities, API-characterization complexity, and insufficient proposed-route safety information. This is a 503A compounding safety-risk bucket, not FDA drug approval.[21][13][14][19][20] |
Injectable
International
EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets.[22][23][24][25]
Sports & competition
WADA S0 can apply to non-approved pharmacological substances that are not otherwise named. Tested athletes should not treat DSIP injectable route as athlete-cleared without sport-specific review.[15][13][14][19][20]
How it works
DSIP has been studied around sleep architecture, stress-axis modulation, pain, and neuroendocrine signaling. In practical terms, the proposed mechanism is state regulation across sleep and stress systems rather than the direct receptor action of a sedative-hypnotic drug.[1][2][3][4]
Injectable use keeps the exposure question separate from old sleep-lab observations. Because the receptor target remains diffuse and modern dose-ranging evidence is thin, the mechanism can explain research interest but cannot carry strong insomnia or recovery claims by itself. Modern trials would need to define both exposure and measurable sleep endpoints.[1][2][3][4]
Research gaps & open questions
What the current literature has not yet settled about DSIP:
Modern randomized trials need to show whether DSIP helps people fall asleep, stay asleep, or feel better the next day compared with placebo.[1][2][3][4]
Researchers have not clearly established which receptor DSIP acts on or how the body absorbs, distributes, and clears it.[1][2][3][4]
Studies have not tested how DSIP interacts with sleep medicines, alcohol, antidepressants, antipsychotics, or other psychiatric drugs.[1][2][3][4]
Common questions
Is DSIP FDA-approved for sleep?
Does DSIP force sleep?
Myths & misconceptions
History & discovery
DSIP was named from early work linking a peptide fraction with delta-wave sleep, then tested in small sleep and pain studies. Its history is old, intriguing, and still unresolved.[1][2][3][4]
Clinical studies tested DSIP in chronic insomnia, 24-hour sleep-wake behavior, and pronounced pain episodes. Those studies created human interest but did not mature into an approved insomnia drug.[1][2][3][4]
Later reviews repeatedly treated DSIP as a mechanistic puzzle rather than a settled therapy. That history explains why modern claims need caution around receptor target, dose, and endpoints.[1][2][3][4]
29 citations
Show citationsHide citations
- [1]Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.Neuropsychobiology, 1992. human clinical.
- [2]Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.Eur Neurol, 1987. human clinical.
- [3]Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study.Eur Neurol, 1984. human clinical.
- [4]Delta sleep-inducing peptide.Eur J Anaesthesiol, 2001 Jul. review.
- [5]Delta sleep-inducing peptide (DSIP): a still unresolved riddle.J Neurochem, 2006 Apr. review.
- [6]Delta-sleep-inducing peptide (DSIP): an update.Peptides, 1986 Nov-Dec. review.
- [7]Delta-sleep-inducing peptide (DSIP): a review.Neurosci Biobehav Rev, 1984 Spring. review.
- [8]DSIP--a tool for investigating the sleep onset mechanism: a review.Int J Neurosci, 1988 Feb. review.
- [9]The effects of delta-sleep-inducing peptide (DSIP) on wakefulness and sleep patterns in the cat.Brain Res, 1987 Jun 30. review.
- [10]Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke.Molecules, 2021 Aug 26. animal.
- [11]Comparison of DSIP- (delta sleep-inducing peptide) and P-DSIP-like (phosphorylated) immunoreactivity in cerebrospinal fluid of patients with senile dementia of Alzheimer type, multi-infarct syndrome, communicating hydrocephalus and Parkinson's disease.J Neurol, 1987 Oct. human clinical.
- [12]Production and immunohistochemical application of monoclonal antibodies against delta sleep-inducing peptide.J Chem Neuroanat, 1992 Nov-Dec. review.
- [13]Drugs@FDA/openFDA query for DSIPU.S. Food and Drug Administration. database query.
- [14]Compounding and the FDA: Questions and AnswersU.S. Food and Drug Administration. official guidance.
- [15]The 2026 List of Prohibited Substances and MethodsWorld Anti-Doping Agency. regulatory.
- [16]Effects of pH, electric current, and enzyme inhibitors on iontophoresis of delta sleep-inducing peptide.Drug development and industrial pharmacy, 1998 May. ex vivo.
- [17]Intranasal administration of delta sleep-inducing peptide increases P300.J Clin Psychopharmacol, 2001 Dec. human clinical.
- [18]FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-RegulatedU.S. Food and Drug Administration. official guidance.
- [19]Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C ActU.S. Food and Drug Administration, 2026-05-14. regulatory.
- [20]Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C ActU.S. Food and Drug Administration, 2025-01-07. regulatory.
- [21]Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration, 2026-04-22. regulatory.
- [22]European Medicines Agency medicines searchEuropean Medicines Agency. official guidance.
- [23]MHRA Products searchMedicines and Healthcare products Regulatory Agency. official guidance.
- [24]Drug Product Database: Access the databaseHealth Canada. official guidance.
- [25]Searching the Australian Register of Therapeutic GoodsTherapeutic Goods Administration. official guidance.
- [26]Cosmetic Products RegulationEuropean Commission. official guidance.
- [27]Making cosmetic products available to consumers in Great BritainUK Office for Product Safety and Standards. official guidance.
- [28]Cosmetics regulatory informationHealth Canada. official guidance.
- [29]Cosmetics and soapAustralian Industrial Chemicals Introduction Scheme. official guidance.


